Human moricizine metabolism. I. Isolation and identification of metabolites in human urine

References

• ARAVAGIRI, M., H AWES, E. M. and MIDHA, K. K., 1984, Radioimmunoassay for the sulfoxide metabolite of Trifluoroperazin e and its application to a kinetic study in humans. Journal of Pharmaceutical Science, 73, 1383–1387.
   PubMed Web of Science ®Google Scholar
• BECKETT, A. H., BEAVEN M. A. and ROBINSON, A. E., 1963, Metabolism of chlorpromazine in humans. Biochemical Pharmacology, 12, 779–794.
   Google Scholar
• BELOBORODOV V. L., RODIONOV, A. P., TYUKAVKINA, N. A., KLDLov, A. V., K AVERINA, N. V., K OLESNIK, Y. A., GRITSENKO, A. N. and LESINA, V. P., 1989, Ethacizin metabolism in humans. Xenobiotica, 19, 755–767.
   Google Scholar
• FITTON, A. and BUCKLEY, M. M.-T., 1990, Moricizine : a review of its pharmacological properties and therapeutic efficacy in cardiac arrhythmias. Drugs, 40, 138–167.
   Google Scholar
• GRITSENKO, A. N., ERMAKOVA, Z. I. and ZHURAVLEV, S. V., 1972, The synthesis of ethmozine : A new preparation with antiarrhythmic action. Khimiko-Farmatsevticheskii Zhurnal, 6, 17–19.
   Google Scholar
• HONDEGHEM, L. M. and K ATZUNG, B. G., 1977, Time- and voltage-dependent interactions of antiarrhythmic drugs with sodium channels. Biochimica et Biophysica Acta, 472, 373–398.
   PubMed Web of Science ®Google Scholar
• KAVERNA, N. V., LYSKOVTSEV, V. V., S ENOVA, Z. P. and GRIGORYEVA, E. K., 1984, Ethacizin: pharmacological properties and prospects of clinical employment. Kardiologiya, 24, 52–57 (in Russian). Cumulated Index Medicus 25, book 4.
   Google Scholar
• KOILER, B. and FRANZ, M. R., 1994, New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart. Journal of Car-diovascular Pharmacology, 24, 753–760.
   Google Scholar
• MAKIELSKI, J. C., 1990, State dependence of Ethacizin and Ethmozin block of sodium current in voltage clamped and internally perfused cardiac Purkinje cells. Journal of Pharmacology and Experimental Therapeutics, 253, 1110–1117.
   Google Scholar
• PERRIN, D. D., DEMPSEY, B. and S ERJEANT, E. P., 1981, pK, Prediction for Organic Acids and Bases (London: Chapman & Hall), pp. 27–31.
   Google Scholar
• PIENIASZEK, H. J. JR, DAVIDSON, A. F., MCENTEGART, C. M., QUON, C. Y., SAMPLINER, R. E. and MAYERSOHN, M., 1994, The effect of hepatic disease on the disposition of moricizine in humans. Biopharmaceutics and Drug Disposition, 15, 243–252.
   Google Scholar
• SCHUBERT, B., HERING, S., B ODEVVEI, R., ROSENSHTRAUKH, L. V. and W OLLENBERGER, A. J., 1986, Use and voltage-dependent depression by Ethmozine (moricizine) of the rapid inward sodium current in single rat ventricular muscle cells. Journal of Cardiovascular Pharmacology, 8, 358–366.
   Google Scholar
• SHEEHAN E. W., 1990, Rat and human urinary metabolites of Ethmozine. PhD thesis, University of Pittsburgh.
   Google Scholar
• SHEEHAN, E. W W ONG, L., ZEMAITIS, M. A., BUCHNER, J. and Lo, H. H., 1985, Studies of Ethmozine metabolism by LC /M SS. In Proceedings of the 33rd Annual Conference on Mass Spectroscopyand Allied Topics, San Diego, CA, 26–31 May, (Sante Fe, New Mexico: American Society for Mass Spectroscopy and Applied Topics) 782–783 (abs).
   Google Scholar
• SHELDON, R. S., HILL, R. J., TAOVIS, M. and WILSON, L. M., 1991, Aminoalkyl structural requirements for interaction of lidocaine with the class 1 antiarrhythmic receptor on rat cardiac myocytes. Molecular Pharmacology, 39, 609–614.
   PubMedGoogle Scholar
• SINGH, B. N. and VAUGHAN WILLIAMS, E. M., 1970, The effect of Amiodarone, a new anti-anginal drug on cardiac muscle. British Journal of Pharmacology, 39, 657–667.
   PubMed Web of Science ®Google Scholar
• SNYDER, D. W., 1989, Class 111 antiarrhythmic drugs: tocainide, mexilitine, and moricizine. Journal of the Louisiana State Medical Society, 141, 21–25.
   Google Scholar
• VAUGHAN W ILLIAMS, E. M., 1992, The relevance of cellular to clinical electrophysiology classifying antiarrhythmic actions. Journal of Cardiovascular Pharmacology, 20 (suppl. 2), S1–7.
   Google Scholar
• VIKHLYAEV, Y. I., ZHERDEV, V. P., GRITSENKO, A. N. and ERMAKOVA, Z. I., 1977, Features of Ethmozin metabolism [English translation]. Farmakologiya i Toksikologiya, 40, 19–22.
   Google Scholar
• WALDO, A. L., ROGERS, W J., PRATT, C. M. and CAPONE, R. J., 1988, Effects of encainide, flecainide, imipramine, and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. American Journal of Cardiology, 61, 501–509.
   Google Scholar
• WEISEL, C. A., TAYLOR, R. B., M OSHER, H. S. and W HITMORE, F. C., 1945, Substituted /3-aminopropionic esters. Journal of the American Chemical Society, 67, 1071–1072.
   Google Scholar
• WHITMORE, F. C., M OSHER, H. S., ADAMS, R. R., T AYLOR, R. B., CAPIN, E. C., WEISEL, C. and YANKO, W., 1944, Basically substituted aliphatic nitriles and their catalytic reduction to amines. Journal of the American Chemical Society, 66, 725–731.
   Google Scholar
• WILSON, I. D., FROMSOM, J. M. and ILLING, H. P. A., 1987, The metabolism of ['4C]N-ethoxycarbony1-3-morpholinosydnonimine (molsidomine) in man. Xenobiotica, 17, 93–104.
   PubMed Web of Science ®Google Scholar
• YANG, J. M. and CHAN, K., 1995, Isolation and characterization of sulphoxidation metabolites of moricizine in rat and human biological fluids. Methods and Findings in Experimental and Clinical Pharmacology, 17, 415–421.
   PubMed Web of Science ®Google Scholar